Systemic Anaplastic Large-Cell Lymphoma

Also known as: Systemic Anaplastic Large Cell Lymphoma / Anaplastic large cell lymphoma, ALK-positive / Large cell anaplastic lymphoma T cell and Null cell type (disorder) / Anaplastic large-cell lymphoma / Anaplastic large cell lymphoma, T cell and Null cell type (morphologic abnormality) / Lymphoma, Large-Cell, Anaplastic

Drug	Drug Name	Drug Description
DB08870	Brentuximab vedotin	A CD30-directed antibody-drug conjugate used to treat various types of lymphoma.

Drug	Drug Name	Target	Type
DB08870	Brentuximab vedotin	Tumor necrosis factor receptor superfamily member 8	target
DB08870	Brentuximab vedotin	Cytochrome P450 3A4	enzyme
DB08870	Brentuximab vedotin	ATP-binding cassette sub-family B member 5	transporter

Drug	Drug Name	Phase	Status	Count
DB08865	Crizotinib	1	Completed	1
DB01167	Itraconazole	1	Completed	1
DB01045	Rifampicin	1	Completed	1
DB08870	Brentuximab vedotin	1 / 2	Withdrawn	1
DB09063	Ceritinib	1 / 2	Withdrawn	1
DB08865	Crizotinib	4	Withdrawn	1